AAM's new CEO will be tasked with handling the renewal of the generic drug user fee program, in addition to stamping out efforts to block generic competition. • Source: Shutterstock
Learn what's happening at the US FDA. On the go.
Derrick Gingery and the team bring you a weekly "Drug Fix".
